BioVersys successfully advances BV500 NTM program with continued support from CF AMR syndicate

Basel, Switzerland. February 11, 2025, 7am CET

• BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against non-tuberculous mycobacteria (NTM).
• Continued strategic support from LifeArc through the CF AMR Syndicate Collaborative Discovery Programme (CDP), accelerating the development of novel therapies for difficult-to-treat NTM lung disease in cystic fibrosis (CF) patients.
• Leveraging its proprietary Ansamycin Chemistry platform, BioVersys’ BV500 molecules are designed to overcome resistance and address highly drug-resistant NTM infections.

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today that its BV500 NTM program has reached its second milestone, “identification of up to 5 Optimized Lead compounds”, under the CF AMR Syndicate Collaborative Discovery Programme (CDP) agreement. Supported by LifeArc funding, BioVersys is developing novel small molecules targeting difficult to treat non-tuberculous mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

The company’s BV500 NTM program is derived from its proprietary Ansamycin Chemistry platform from which the research team has identified and is developing several advanced, highly potent ansamycin oral Lead candidates, with broad-spectrum in vitro and in vivo anti-NTM activity, and which are devoid of cross-resistance with other therapeutic classes.

Dr. Nawaz Khan, Head of Research at BioVersys: “We are very pleased with the progress of our BV500 program, the fourth of a series of successful pipeline programs, targeting high unmet medical need in antimicrobial resistance (AMR). Together with our collaboration partners from the CF AMR Syndicate (LifeArc, Medicines Discovery Catapult and Cystic Fibrosis Trust), we continue to show how successful partnerships can be developed to address patients suffering with difficult to treat NTM-LD, through synergizing a broad range of complementary expertise.”

Dr. Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge at LifeArc: “Addressing the urgent challenge of NTM lung disease in people with cystic fibrosis requires innovation and collaboration. The progress of the BV500 program demonstrates the impact of bringing together scientific expertise to accelerate the development of much-needed treatments. We are proud to support BioVersys in advancing this promising research, with the shared goal of improving outcomes for patients.”

Full PR available here